CN Patent

CN121620364A — 治疗运动障碍的组合物和方法

Assigned to Climax Labs Inc · Expires 2026-03-06 · 0y expired

What this patent protects

本公开涉及治疗运动障碍的组合物和方法，其使用包含3‑甲基甲卡西酮（3MMC）或其药学上可接受的盐的药物组合物。

USPTO Abstract

本公开涉及治疗运动障碍的组合物和方法，其使用包含3‑甲基甲卡西酮（3MMC）或其药学上可接受的盐的药物组合物。

Drugs covered by this patent

Reglan (Metoclopramide Hydrochloride) · Hikma

Patent Metadata

Patent number: CN121620364A
Jurisdiction: CN
Classification: —
Expires: 2026-03-06
Drug substance claim: No
Drug product claim: No
Assignee: Climax Labs Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.